Table 2.

Trial adherence

	Levetiracetam (n=152)	Phenytoin (n=134)	Total (n=286)
Patient given lower dose of trial treatment	8 (5%)	4 (3%)	12 (4%)
Patient given higher dose of trial treatment	2 (1%)	1 (<1%)	3 (1%)
Dose administration shorter than expected	0	1 (<1%)	1 (<1%)
Dose administration longer than expected	27 (18%)	34 (25%)	61 (21%)
Treatment prematurely discontinued	0	2 (1%)	2 (<1%)
Unauthorised route of administration (intraosseous)	6 (4%)	0	6 (2%)
Received initial second-line treatment other than that allocated	3 (2%)	0	3 (<1%)
Received further second-line treatment*	22 (14%)	13 (10%)	35 (12%)

^*Includes those who subsequently received the alternative trial treatment or an additional dose of the allocated treatment, within 24 h.